CTOs on the Move


 
Medterra takes pride in providing our customers with the highest quality pure CBD, grown and processed in the USA.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Cano Health

Cano Health operates healthcare centers specializing in Senior Care and Primary Care for all ages. In addition to primary medical care, Cano Health has specialty programs in the fields of Venous Medicine, Arthritis, Allergy, and Weight Loss. OUR MISSION Our mission is to improve patient health by delivering superior primary care medical services, while forging a life-long bond with our members. OUR VISION Our vision is to become the national leader in primary care by improving the health, wellness, and quality of life of the communities we serve, while reducing health care costs.

MERIAL Limited

MERIAL Limited is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. MERIAL Limited is based in Duluth, GA. You can find more information on MERIAL Limited at www.merial.com

Creative Community Living

Creative Community Living is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Winfield, KS. To find more information about Creative Community Living, please visit www.cclccl.org

Foghorn Therapeutics

More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes? Foghorn® Therapeutics ($FHTX) is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control™ platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease. With Gene Traffic Control™ Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.